
Biorelate is a biopharmaceutical company that leverages its proprietary platform, Galactic AI™, to revolutionize biomedical data curation and accelerate drug discovery. The platform uses AI-led curation to identify and curate cause-and-effect relationships within vast amounts of biomedical literature, enabling scientists to uncover novel targets, validate hypotheses, understand mechanisms of action, and expand indications. Biorelate's technology processes millions of documents to create a comprehensive knowledge graph in biopharma, offering insights that traditional methods might miss. The company serves a wide range of clients, from large pharmaceutical companies to smaller biotech firms, aiming to accelerate the pace of innovation and bring life-saving therapeutics to market.

Biorelate is a biopharmaceutical company that leverages its proprietary platform, Galactic AI™, to revolutionize biomedical data curation and accelerate drug discovery. The platform uses AI-led curation to identify and curate cause-and-effect relationships within vast amounts of biomedical literature, enabling scientists to uncover novel targets, validate hypotheses, understand mechanisms of action, and expand indications. Biorelate's technology processes millions of documents to create a comprehensive knowledge graph in biopharma, offering insights that traditional methods might miss. The company serves a wide range of clients, from large pharmaceutical companies to smaller biotech firms, aiming to accelerate the pace of innovation and bring life-saving therapeutics to market.
Founded: 2014
Headquarters: Manchester/Oldham, UK
Product: Galactic AI — AI/NLP biomedical literature curation and knowledge graph
Use cases: Target discovery, validation, mechanism-of-action insights, biomarker research
Latest disclosed round: Series A (Nov 29, 2022)
Biomedical literature curation and knowledge-graph generation to support drug discovery and translational research.
2014
Biotechnology
£6.5M (~$7.82M)
Series A announced November 29, 2022
“Catapult Ventures; GM&C Life Sciences Fund; Manchester Tech Trust Angels; Maven Capital Partners; NPIF Maven Equity Finance; Northern Powerhouse Investment Fund; Triple Point Ventures; YFM Equity Partners”